Prescient Therapeutics Ltd
PTX
Company Profile
Business description
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
Contact
Level 4, 100 Albert Road
South Melbourne
MelbourneVIC3205
AUST: +61 396927222
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
12
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,641.80 | 10.30 | 0.12% |
| CAC 40 | 7,826.79 | 1.34 | -0.02% |
| DAX 40 | 24,226.49 | 198.84 | 0.83% |
| Dow JONES (US) | 42,343.65 | 740.58 | 1.78% |
| FTSE 100 | 8,778.05 | 60.08 | 0.69% |
| HKSE | 23,276.60 | 105.39 | -0.45% |
| NASDAQ | 19,199.16 | 461.96 | 2.47% |
| Nikkei 225 | 37,918.86 | 194.75 | 0.52% |
| NZX 50 Index | 12,379.59 | 202.74 | -1.61% |
| S&P 500 | 5,921.54 | 118.72 | 2.05% |
| S&P/ASX 200 | 8,411.20 | 3.60 | 0.04% |
| SSE Composite Index | 3,341.78 | 1.09 | 0.03% |